The TDP is a digital initiative that aims to increase the secondary use of clinical trials and studies and extract even more value from patient samples.
Oxford Cancer and the Oxford ECMC have announced the expansion of the available data to include the METFORMIN - Effect of Metformin on Breast Cancer Metabolism study. In this study, samples from 36 patients with untreated primary breast cancer were profiled before and after metformin treatment.
For each patient, paired PET-CT scans, immunohistochemistry, RNAseq and tumour and patient characteristics are available in a quality-controlled, easily accessible form. Oxford scientists can analyse the data through a bespoke cBioportal page, or can download the data for more advanced analysis.
Information from 800 colorectal patients, 250 oesophageal cancer patients and nearly 80 breast cancer patients is already available through the TDP, with new trials and studies added regularly.
To request access email sara.danielli@medsci.ox.ac.uk.